Growth Funding KdT Ventures recently closed a new fund of over $100M to back early-stage, science-driven companies, signaling ongoing capacity for larger follow-on investments and expanded deal sourcing in tech-health convergence spaces.

Science Tech Focus The firm emphasizes the intersection of technology and science, with a thesis around advances in compute enabling addressable problems, suggesting opportunity to partner with startups at seed stage that blend computational methods with scientific innovation.

Leadership Growth Recent promotions to managing partner and partner indicate strategic focus on leadership, potentially increasing engagement with portfolio companies for hands-on guidance, governance support, and network-driven fundraising.

Active Portfolio Investments and exits in biotech, protein engineering, digital health, and rare disease initiatives (e.g., NGM313 and Aperiam Bio) point to target prospects in life sciences with scalable tech applications and potential co-investor collaboration.

Collaboration Signals Past co-investments with notable firms and a broad syndication in seed rounds (e.g., Marigold Health, Terraytx) suggest warm introductions and partnership potential for co-led rounds, strategic partnerships, and joint market access initiatives.